Monopoly is a protean key word in American law and politics. In his first solo book, Joseph Gabriel reminds the reader that during the nineteenth century, it was also a key word in American medicine, in ways that were profoundly linked to law. Medical Monopoly examines the origins of the modern pharmaceutical industry in the interplay between medical ethics and the assertion of intellectual property rights, an interplay mediated by a medical understanding of monopoly. This understanding changed radically during the long nineteenth century. Gabriel analyzes this change as expressed through codes of ethics and in the practices of making, selling, and dispensing medicines from the early republic through World War I. Although he pays close attention to the changes in statutory and case law, and draws knowledgeably upon the legal secondary literature as well as the historiography of medicine and business, Gabriel's primary actors are physicians, pharmacists, and drug manufacturers.
The modern pharmaceutical industry is often portrayed as a triumph of intellectual property. In this common narrative, corporations use patents to link innovation to profits in ways that ensure a steady stream of new cures. Trademarks allow them to monetize brand loyalty even after a drug's patent has expired, distinguishing brand name from generic pharmaceuticals. Gabriel teaches that this orderly harnessing of intellectual property rights became possible only after dramatic changes in the law, business, and ethics of drugs. The taken-for-granted link between innovation and profits that grounds the modern pharmaceutical industry needed to be forged. One of Gabriel's central arguments is that its forging required a significant reconfiguration of medical ethics.
In the decades before the Civil War, the medical profession and many pharmacists made opposition to monopoly an ethical stance that required eschewing any form of intellectual property. In ways alien to contemporary thought, they understood patents and trade secrets not as opposites, but as two almost interchangeable forms of monopoly. Later, trademarks also came to be seen as forms of monopoly. The use of any of these strategies in the drug trade was considered deeply unethical, and was pejoratively referred to as “quackery.” Monopoly via such practices was unethical because it was the opposite of what physicians called “scientific medicine.” Scientific medicine was idealized as a gradual, communal process of developing and testing new cures. Any potential treatment should be communicated to the entire profession and only once it had been well vetted through use with patients should it be made and sold. So-called “ethical” medicines could be neither secret nor patented. Further, physicians and pharmacists were concerned with what Gabriel calls the “relationship between names and things” (4), that is, with identifying the unique name for each medicine by which it should be sold and prescribed so that all physicians and patients were confident about what was being used. Part of Gabriel's story is the constant effort of professional organizations of pharmacists and physicians to develop official registries, “pharmacopeias,” to create and stabilize names, as the industry struggled toward today's neat divide between generic names and trademarked brand names.
Gabriel describes the early pharmaceutical industry as divided into two sectors. These were the so-called patent medicine manufacturers, who usually used trade secrets, rather than patents, to protect their proprietary recipes, and the so-called ethical manufacturers, whose primary claim to ethical behavior was their avoidance of both patents and secrecy. Those familiar with contemporary patent doctrines will appreciate that many early medicines were outside the scope of patent protection, whatever the ethics of the matter. This possible additional motivation for the ethical stance against patents is underexplored in the book, although Gabriel does devote some attention to questions of novelty, utility, and the product of nature doctrine. As Gabriel explores in his final chapter, the origins of the latter are firmly linked to the pharmaceutical industry in cases such as Parke-Davis v. Mulford (1911), a patent battle between two self-described ethical manufacturers that marks the change in attitude Gabriel describes.
Having explained this marketplace and the way ethical practices and codes were used to constrain the drug business in the first three chapters, in the next three chapters Gabriel traces the slow unraveling of the opposition to medical monopoly via intellectual property. The emergence of novel and efficacious laboratory-made drugs from the 1870s onward offered both new possibilities of strong patent protection and the entry of foreign and domestic chemical manufacturers, players who lacked any sense of obligation to medical ethics, into drug manufacturing. When the new patented drugs, such as phenacetin (an anti-fever drug) and Salvarsan (a treatment for syphilis), offered great curative potential, physicians had difficulty maintaining their ethical objections to patented medicines. Instead, aided by the careful rhetoric and evolving practices of the ethical manufacturers, who very much wanted to enter this new competitive space of drug discovery, physicians ultimately embraced patents as ethical means of promoting innovation, and amended their ethical codes accordingly.
To legal historians interested in the regulatory state and corporate capitalism, Gabriel's well-researched book offers new insight into monopoly as an analytic category and antimonopoly sentiment as a driver for law and policy. Gabriel also provides a unique perspective on the development of modern intellectual property, a story not previously told from the viewpoint of pharmacists and travelling drug salesmen. He reminds readers to look beyond lawyers and their clients as he traces the influence of physicians and their attempts to reap the harvest of scientific medicine on both the practices of the drug industry and on evolving legal doctrines.
